The complexity of the treatment of patients with chronic lymphocytic leukemia has increased
substantially over the past several years as a consequence of the advent of novel biological …

The introduction of chemoimmunotherapy and more recently the implementation of novel
agents into first-line and relapse treatment have substantially improved treatment outcomes …

The ultimate cause of death for most patients with newly diagnosed chronic lymphocytic
leukaemia (CLL) and its relationship to co‐morbid health conditions is poorly defined. We …

BACKGROUND Most patients with chronic lymphocytic leukemia (CLL) present with multiple
comorbidities. Although comorbidities negatively affect outcomes for patients treated with …

Abstract The European Society for Medical Oncology (ESMO) consensus conference on
mature B cell lymphomas and chronic lymphocytic leukaemia (CLL) was held on 20 June …

Background: Refeeding syndrome is a potentially fatal shift of fluids and electrolytes that
may occur after reintroducing nutrition in a malnourished patient. Its incidence in internal …

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different
manifestations of the same disease, which are managed in the same way. The advent of …

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different
manifestations of the same disease and managed in much the same way. The advent of …

In this population-based study, we used the SEER database (1985–2015) to examine
survival outcomes in chronic lymphocytic leukemia (CLL) patients followed up to the era of …

BACKGROUND Although the combination of rituximab, cyclophosphamide, doxorubicin,
vincristine, and prednisone (R‐CHOP) is considered standard therapy for diffuse large B …